Editorial

HORMONE THERAPY IN FEMALES AND GENITAL CARCINOMA

Ante Ćorušić
Marina Šprem
Dinka Pavičić-Baldani
Branka Petričević
Višnja Matković

Abstract

Tamoxifen and other selective estrogen receptor modulators are new medications characterised by high estrogen receptor affinity. In certain tissues they express estrogen-like activity and in the others they act as estrogen antagonists. This review discussess their use in breast and endometrial carcinoma as well as their treatment results. It also reviews their potential effects on ovarial and cervical carcinoma. According to numerous clinical trials tamoxifen has proved effective in breast cancer treatment of premenopausal and postmenopausal women. The risks of this therapy, such as development of secondary endometrial carcinoma, have also been presented. The use of gestagenes in endometrial carcinoma treatment has been discussed too. This paper reviews the influence of hormone replacement therapy on the development of breast and endometrial carcinoma as well as the safety of its application in patients diseased of breast, endometrial, ovarian or cervical carcinoma.

Keywords

hormone therapy; genital carcinoma

Hrčak ID:

15538

URI

https://hrcak.srce.hr/15538

Publication date:

1.12.2003.

Article data in other languages: croatian

Visits: 3.200 *